Kripthonite Therapeutics ApS
Private limited companyCVR 43770209Aarhus NActive
Kripthonite Therapeutics ApS is a private limited company, based in Aarhus N, active in manufacture of pharmaceutical preparations, founded in 2023. The company made a loss in both 2024 and 2025, most recently DKK 3.9m. Equity grew to DKK 4.6m in 2025. 6 other companies in the database are registered at the same address.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- Gross profit fell 2,900% (2024 → 2025), to −DKK 3.5m.
- The loss grew: from DKK 32 to DKK 3.9m (2024 → 2025).
- Equity rose 13,205% (2024 → 2025), to DKK 4.6m.
Employees
- 2 more employees than a year earlier: 4 (07/2026) against 2 (07/2025).
Management and owners, last 24 months
- New in management: Jan Stenvang (director, 19/02/2026), Erik Vinther (board member, 19/02/2026) and Carsten Grøhn (chair of the board, 14/10/2026) (+2).
- Stepped down: Peter Horn Møller (chair of the board, 30/09/2025), Erik Vinther (director, 19/02/2026) and Peter Horn Møller (board member, 19/02/2026) (+1).
- New owners registered: Marigold Innovation ApS (01/05/2025), Thomas B. Poulsen Holding ApS (01/05/2025) and Hjerrild Chemistry Consulting ApS (01/05/2025) (+3).
- No longer registered as owner: Marigold Innovation ApS (30/04/2025), Thomas B. Poulsen Holding ApS (30/04/2025) and Hjerrild Chemistry Consulting ApS (30/04/2025) (+2).
Registrations, last 24 months
- 01/11/2025: Share capital changed from 45,000 DKK to 47,813 DKK
- 31/07/2025: Share capital changed from 42,500 DKK to 45,000 DKK
- 26/05/2025: Moved to Palle Juul-Jensens Boulevard 82, 8200 Aarhus N
- 01/05/2025: Share capital changed from 40,000 DKK to 42,500 DKK
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2023–2025 · amounts in DKK thousandEquity and net profit
| 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | – |
| Gross profit | 542 | 125 | −3,513 | −2,900.3% |
| Operating profit (EBIT) | −5 | 0 | −4,944 | – |
| Profit before tax | −5 | −0 | −4,967 | −15,522,206.3% |
| Net profit | −5 | −0 | −3,936 | −12,300,756.3% |
| Total assets | 75 | 169 | 4,793 | +2,744.6% |
| Equity | 35 | 35 | 4,598 | +13,204.8% |
| Liabilities | 41 | 134 | 195 | +45.6% |
| Cash and cash equivalents | 30 | 164 | 3,471 | +2,016.2% |
| Average number of employees | 1 | 1 | 1 | 0% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresLoss for 3 years in a row
Net result has been negative in 2023–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
3 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 27/03/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 31/05/2025 | The company | PDFXBRL |
| 2023 | 10/01/2023 – 31/12/2023 | 14/05/2024 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
59 companies in the databaseComparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.
Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 69,427of 69,742 Better than 0% | No. 14,953of 69,964 Better than 79% |
| Same industry and fewer than 20 employees37 companies in the comparison | No. 26of 36 Better than 29% | No. 14of 37 Better than 64% |
| Companies that are founded within the last five years16,662 companies in the comparison | No. 16,516of 16,614 Better than 1% | No. 1,383of 16,661 Better than 92% |
| All companies of type ApS66,508 companies in the comparison | No. 66,113of 66,379 Better than 0% | No. 11,938of 66,505 Better than 82% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Manufacture of pharmaceutical preparations- Kripthonite Therapeutics ApS−DKK 3.5m
- Novo Nordisk A/SDKK 250.3bn
- H. Lundbeck A/SDKK 20.4bn
- Kripthonite Therapeutics ApS−DKK 3.9m
- Novo Nordisk A/SDKK 102.4bn
- H. Lundbeck A/SDKK 3.2bn
- Kripthonite Therapeutics ApSDKK 4.6m
- Novo Nordisk A/SDKK 194bn
- H. Lundbeck A/SDKK 24.9bn
- Kripthonite Therapeutics ApS4
- Novo Nordisk A/S27,279
- H. Lundbeck A/S2,261
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- Marigold Innovation ApS20%
- Thomas B. Poulsen Holding ApS20%
- Hjerrild Chemistry Consulting ApS20%
- Jacobsen Biotech ApS20%
- Marigold Maturation Fund K/S15%
Management
6 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Jan Stenvang | Director | 19/02/2026 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Thomas Bjørnskov Poulsen | Board member | 10/01/2023 |
| Kristian Mark Jacobsen | Board member | 10/01/2023 |
| Per Hjerrild | Board member | 10/01/2023 |
| Erik Vinther | Board member | 19/02/2026 |
| Carsten Grøhn | Chair of the board | 14/10/2026 |
- Founders
- Marigold Innovation ApS, Thomas B. Poulsen Holding ApS, Hjerrild Chemistry Consulting ApS, Jacobsen Biotech ApS
Former management (4)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Peter Horn Møller | Chair of the board | 10/01/2023 | 30/09/2025 |
| Erik Vinther | Director | 10/01/2023 | 19/02/2026 |
| Peter Horn Møller | Board member | 01/10/2025 | 19/02/2026 |
| Søren Bregenholt Frederiksen | Chair of the board | 01/10/2025 | 14/10/2026 |
Signing rule: Selskabet tegnes af to bestyrelsesmedlemmer i forening.
Address and production units
1 active production unitsPalle Juul-Jensens Boulevard 82
8200 Aarhus N
Aarhus Municipality · Postcode 8200
Other companies at the address (6)
- NMD Pharma A/SResearch and experimental development on natural sciences and engineering
- Teitur Trophics ApSResearch and experimental development on natural sciences and engineering
- MedicQuant ApSManufacture of medical and dental instruments and supplies
- Starzen Europe ApSWholesale of meat and meat products
- MD Teacher ApSOther education n.e.c.
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Kripthonite Therapeutics ApS | Palle Juul-Jensens Boulevard 82, 8200 Aarhus N | 4 | 1028917135 |
Purpose
Selskabets formål er forskning og udvikling af lægemidler og dermed beslægtet virksomhed.
The purpose is quoted from the register in Danish.
Changes year by year
37 registered events20267 changesmanagement 6 · accounts 1
- ManagementCarsten Grøhn appointed chair of the board
- ManagementSøren Bregenholt Frederiksen stepped down as chair of the board
- AccountsAnnual report for 2025 published
- ManagementJan Stenvang appointed director
- ManagementErik Vinther appointed board member
- ManagementPeter Horn Møller stepped down as board member
- ManagementErik Vinther stepped down as director
202519 changescapital 3 · ownership 11 · management 3 · accounts 1 · address 1
- CapitalShare capital changed from 45,000 DKK to 47,813 DKK
- OwnershipMarigold Maturation Fund K/S registered as owner (15%)
- OwnershipMarigold Maturation Fund K/S is no longer registered as owner
- ManagementSøren Bregenholt Frederiksen appointed chair of the board
- ManagementPeter Horn Møller appointed board member
- ManagementPeter Horn Møller stepped down as chair of the board
- CapitalShare capital changed from 42,500 DKK to 45,000 DKK
- AccountsAnnual report for 2024 published
- AddressMoved to Palle Juul-Jensens Boulevard 82, 8200 Aarhus N
- CapitalShare capital changed from 40,000 DKK to 42,500 DKK
- OwnershipMarigold Innovation ApS registered as owner (20%)
- OwnershipMarigold Maturation Fund K/S registered as owner (10%)
- OwnershipThomas B. Poulsen Holding ApS registered as owner (20%)
- OwnershipHjerrild Chemistry Consulting ApS registered as owner (20%)
- OwnershipJacobsen Biotech ApS registered as owner (20%)
- OwnershipHjerrild Chemistry Consulting ApS is no longer registered as owner
- OwnershipJacobsen Biotech ApS is no longer registered as owner
- OwnershipThomas B. Poulsen Holding ApS is no longer registered as owner
- OwnershipMarigold Innovation ApS is no longer registered as owner
20241 changeaccounts 1
- AccountsAnnual report for 2023 published
202310 changesfounded 1 · management 5 · ownership 4
- FoundedRegistered as Kripthonite Therapeutics ApS
- ManagementKristian Mark Jacobsen appointed board member
- ManagementErik Vinther appointed director
- ManagementThomas Bjørnskov Poulsen appointed board member
- ManagementPeter Horn Møller appointed chair of the board
- ManagementPer Hjerrild appointed board member
- OwnershipHjerrild Chemistry Consulting ApS registered as owner (25%)
- OwnershipJacobsen Biotech ApS registered as owner (25%)
- OwnershipThomas B. Poulsen Holding ApS registered as owner (25%)
- OwnershipMarigold Innovation ApS registered as owner (25%)
Related companies
Same people in management
- Scanmetals A/Svia Carsten Grøhn
- Refshaleøens Ejendomsselskab A/Svia Carsten Grøhn
- Udviklingsselskabet Carlsberg Byen P/Svia Carsten Grøhn
- Zyneyro ApSvia Erik Vinther
- Marigold Investment Management ApSvia Peter Horn Møller
- Heimstaden Domus Vista ApSvia Carsten Grøhn
Largest in the industry
- Novo Nordisk A/SDKK 250.3bn
- H. Lundbeck A/SDKK 20.4bn
- Leo Pharma A/SDKK 8.2bn
- Alk-abelló A/SDKK 4.2bn
- Bavarian Nordic A/SDKK 3bn
- Pharmacosmos A/SDKK 1.6bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.